KalVista Pharmaceuticals (KALV) Net Income towards Common Stockholders Growth (3y) (2019 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -10.84% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 26.38% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 34.98% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 47.10% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -32.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -32.12% |
| Apr 30, 2025 | 51.61% |
| Oct 31, 2024 | -24.00% |
| Jul 31, 2024 | -28.09% |
| Apr 30, 2024 | 54.03% |
| Jan 31, 2024 | -32.35% |
| Oct 31, 2023 | -32.03% |
| Jul 31, 2023 | -25.70% |
| Apr 30, 2023 | -53.23% |
| Jan 31, 2023 | -28.51% |
| Oct 31, 2022 | -42.53% |
| Jul 31, 2022 | -42.69% |
| Apr 30, 2022 | -34.62% |
| Jan 31, 2022 | -64.49% |
| Oct 31, 2021 | -70.68% |
| Jul 31, 2021 | -40.62% |
| Apr 30, 2021 | -199.94% |
| Jan 31, 2021 | -33.74% |
| Oct 31, 2020 | -36.17% |
| Jul 31, 2020 | -42.25% |
| Apr 30, 2020 | -26.93% |
| Jan 31, 2020 | -16.29% |
| Oct 31, 2019 | -27.47% |
| Jul 31, 2019 | -26.10% |